Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co.

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Shares of Eli Lilly & Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by fears of a global economic fallout from President Donald Trump’s ...

RICHMOND, CA, USA I April 03, 2025 I Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license ...

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Shares of Sangamo Therapeutics climbed after the genomic medicine company entered a licensing agreement with Eli Lilly for STAC-BBB. The stock rose 31% to 81 cents on volume of 3.1 million shares in ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is ...

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...